LJAC
CRNX icon

L.J. Altfest & Co’s Crinetics Pharmaceuticals CRNX Stock Holding History

L.J. Altfest & Co’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,412
Closed -$225K – 339
2025
Q3 		$225K Sell
5,412
-2,041
-27% -$65.3K 0.03% 314
2025
Q2 		$214K Buy
+7,453
New +$230K 0.03% 316

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

L.J. Altfest & Co's CRNX Position: Q4 2025 in Review

L.J. Altfest & Co sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 5,412 shares — an estimated $225K sold.

L.J. Altfest & Co first reported a position in CRNX in Q2 2025 and held it in 2 quarters. The position peaked at $225K in Q3 2025. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • L.J. Altfest & Co reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • L.J. Altfest & Co sold 5,412 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $225K.
  • L.J. Altfest & Co first reported a position in Crinetics Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • L.J. Altfest & Co's Crinetics Pharmaceuticals position peaked at $225K in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on L.J. Altfest & Co's 13F filing for Q4 2025, filed 23 Jan 2026.